Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


States subpoena J&J information

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson reveals multiple state attorneys general are seeking documents related to the April McNeil Consumer Healthcare recalls of Children's Tylenol and other pediatric liquid OTCs. Company officials said during a recent earnings call that the U.S. Attorney's Office for the Eastern District of Pennsylvania issued a grand jury subpoena related to the McNeil recalls (1"The Tan Sheet" July 26, 2010). The company said Aug. 11 in its fiscal 2010 second-quarter Security Exchange Commission filing that it has received civil investigative demands from other states as well. The firm does not expect the legal proceedings to adversely impact its financial condition

You may also be interested in...

McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena

Investment analysts are confident in Johnson & Johnson's long-term viability even though recalls of OTC drugs and the temporary closure of the facility where the products were made prompted the firm to slash full-year profits estimates and triggered a federal investigation

ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use

The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.

ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts